EDGAR Filing Documents for 0000891293-17-000127

Form 8-K - Current report:

SEC Accession No. 0000891293-17-000127

Filing Date

2017-11-28

Accepted

2017-11-28 17:13:18

Documents

Period of Report

2017-11-28

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	cti-svbloanform8xk11x27x17_.htm	8-K	47493
2	EXHIBIT 4.1	warrant-xsvb.htm	EX-4.1	79322
3	EXHIBIT 4.2	warrant-xlslii.htm	EX-4.2	90927
4	EXHIBIT 10.1	loanandsecurityagreement.htm	EX-10.1	295181
	Complete submission text file	0000891293-17-000127.txt		514402

Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121

Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100

CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)